Recently, 21 founder and recurrent mutations in BRCA1/2, PALB2, RAD51C, and CHEK2 genes have been analyzed in a large Polish case-control study including 2270 ovarian cancer patients and 1743 controls. This evidence concerns the gene CHEK2 and ovarian cancer.